Anandamide Oxidation by Wild-Type and Polymorphically Expressed CYP 2 B 6 and CYP 2 D 6

No abstract is available for this paper.

• Publication year

  2011

• Venue

  Unknown venue

• Publication date

  Unknown publication date

• Fields of study

  Not labeled

• Identifiers

  No identifiers available.

• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Opioids Activate Brain Analgesic Circuits Through Cytochrome P450/Epoxygenase Signaling

  2010cited by this paper
• Oxidation of the Endogenous Cannabinoid Arachidonoyl Ethanolamide by the Cytochrome P450 Monooxygenases: Physiological and Pharmacological Implications

  2010cited by this paper
• Quantification of brain endocannabinoid levels: methods, interpretations and pitfalls

  2010cited by this paper
• Targeting Fatty Acid Amide Hydrolase (FAAH) to Treat Pain and Inflammation

  2009cited by this paper
• A Cytochrome P450-Derived Epoxygenated Metabolite of Anandamide Is a Potent Cannabinoid Receptor 2-Selective Agonist

  2009cited by this paper
• Attenuation of Experimental Autoimmune Hepatitis by Exogenous and Endogenous Cannabinoids: Involvement of Regulatory T Cells

  2008cited by this paper
• Targeting the endocannabinoid system: to enhance or reduce?

  2008cited by this paper
• The Endocannabinoid Anandamide Is a Substrate for the Human Polymorphic Cytochrome P450 2D6

  2008cited by this paper
• Cannabinoid Receptors: Where They are and What They do

  2008cited by this paper
• Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects.

  2007cited by this paper
• Anandamide Metabolism by Human Liver and Kidney Microsomal Cytochrome P450 Enzymes to Form Hydroxyeicosatetraenoic and Epoxyeicosatrienoic Acid Ethanolamides

  2007cited by this paper
• Soluble Epoxide Hydrolase: A Novel Therapeutic Target in Stroke

  2007cited by this paper
• Polymorphic CYP2B6: molecular mechanisms and emerging clinical significance.

  2007cited by this paper
• Ciliary targeting of olfactory CNG channels requires the CNGB1b subunit and the kinesin-2 motor protein, KIF17.

  2006influential reference
• Pharmacological actions of cannabinoids.

  2005cited by this paper
• Influence of CYP2B6 polymorphism on plasma and intracellular concentrations and toxicity of efavirenz and nevirapine in HIV-infected patients

  2005cited by this paper
• Genetic variability of CYP2B6 in populations of African and Asian origin: allele frequencies, novel functional variants, and possible implications for anti-HIV therapy with efavirenz

  2005cited by this paper
• Anandamide as an intracellular messenger regulating ion channel activity.

  2005cited by this paper
• The Unique Regulation of Brain Cytochrome P450 2 (CYP2) Family Enzymes by Drugs and Genetics

  2004cited by this paper
• Anandamide content is increased and CB1 cannabinoid receptor blockade is protective during transient, focal cerebral ischemia.

  2004cited by this paper
• Pharmacogenetic determinants of interindividual variability in bupropion hydroxylation by cytochrome P450 2B6 in human liver microsomes.

  2004influential reference
• Effect of genetic polymorphism on the metabolism of endogenous neuroactive substances, progesterone and p-tyramine, catalyzed by CYP2D6.

  2004cited by this paper
• A Cyclooxygenase Metabolite of Anandamide Causes Inhibition of Interleukin-2 Secretion in Murine Splenocytes

  2004cited by this paper
• CYP2D in the brain.

  2003cited by this paper
• Bupropion and 4-OH-bupropion pharmacokinetics in relation to genetic polymorphisms in CYP2B6.

  2003cited by this paper
• Smoking, alcoholism and genetic polymorphisms alter CYP2B6 levels in human brain.

  2003cited by this paper
• A single nucleotide polymorphism of CYP2b6 found in Japanese enhances catalytic activity by autoactivation.

  2001cited by this paper
• Extensive genetic polymorphism in the human CYP2B6 gene with impact on expression and function in human liver.

  2001cited by this paper
• A truncation of 2B subfamily cytochromes P450 yields increased expression levels, increased solubility, and decreased aggregation while retaining function.

  2001cited by this paper
• Heterologous expression of cytochrome P450 2D6 mutants, electron transfer, and catalysis of bufuralol hydroxylation: the role of aspartate 301 in structural integrity.

  2001cited by this paper
• CYP2B6 mediates the in vitro hydroxylation of bupropion: potential drug interactions with other antidepressants.

  2000cited by this paper
• Expression of human cytochrome P450 2B6 in Escherichia coli: characterization of catalytic activity and expression levels in human liver.

  2000cited by this paper
• Validation of bupropion hydroxylation as a selective marker of human cytochrome P450 2B6 catalytic activity.

  2000cited by this paper
• Role of the alanine at position 363 of cytochrome P450 2B2 in influencing the NADPH- and hydroperoxide-supported activities.

  1998cited by this paper
• Molecular characterization of human and mouse fatty acid amide hydrolases.

  1997cited by this paper
• Polymorphism of the cytochrome P450 CYP2D6 gene in a European population: characterization of 48 mutations and 53 alleles, their frequencies and evolution.

  1997cited by this paper
• The rabbit pulmonary cytochrome P450 arachidonic acid metabolic pathway: characterization and significance.

  1995cited by this paper
• Differential activation of cyclophosphamide and ifosphamide by cytochromes P-450 2B and 3A in human liver microsomes.

  1993cited by this paper
• Enzymatic synthesis and degradation of anandamide, a cannabinoid receptor agonist.

  1993cited by this paper
• Cytochrome P450 and the arachidonate cascade 1

  1992cited by this paper
• Structure of a cannabinoid receptor and functional expression of the cloned cDNA

  1990influential reference

• Endocannabinoid signaling pathways: beyond CB1R and CB2R

  2021cites this paper
• The Biosynthesis of Enzymatically Oxidized Lipids

  2020cites this paper
• Neuroprotection in Oxidative Stress-Related Neurodegenerative Diseases: Role of Endocannabinoid System Modulation

  2017cites this paper
• Interindividual Variability in Cytochrome P450–Mediated Drug Metabolism

  2016cites this paper
• Prostaglandins and Other Lipid Mediators eview oluble epoxide hydrolase inhibition , epoxygenated fatty acids and nociception

  2011cites this paper